FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Opdivo Approved in First-Line Bladder Cancer

FDA approves Bristol Myers Squibbs Opdivo (nivolumab) for combination use with cisplatin and gemcitabine for first-line treatment of adult patients wi...

latest-news-card-1

6 Reps Want FDA Voucher for Valley Fever

Five House Republicans and one Democrat from Arizona and California call on FDA to add Valley Fever to the list of tropical diseases eligible for the ...

latest-news-card-1
Medical Devices

Medtronic Class 1 Recall of Duet Drainage Device

FDA classifies as Class 1 a Medtronic Neurology recall of its Duet External Drainage and Monitoring System due to the potential for catheter disconnec...

latest-news-card-1
Federal Register

2 ICH Analytical Procedure Guides Available

Federal Register notice: FDA makes available two International Council for Harmonization final guidances entitled Q2(R2) Validation of Analytical Proc...

latest-news-card-1
Federal Register

Gastrointestinal Drugs Committee Renewal

Federal Register notice: FDA renews its Gastrointestinal Drugs Advisory Committee for an additional two years beyond the charter expiration date.

latest-news-card-1
Medical Devices

Ventec Life Recalls VOCSN Breathing Package

Ventec Life Systems recalls its VOCSN Patient Breathing Package due to a manufacturing issue that causes the bonded spiral wrap to detach before or du...

latest-news-card-1
Human Drugs

ICH Analytical Procedure Development Guidance

FDA publishes the ICH Q14 guidance on analytical procedure development.

latest-news-card-1

Use Healthcare AI for Patients First: Califf

FDA commissioner Robert Califf expresses fears that healthcare artificial intelligence will be used by health systems to make financial decisions rath...

latest-news-card-1
Human Drugs

ICH Analytical Procedure Validation Guidance

FDA publishes the ICH Q2(R2) guidance on validating analytical procedures.

latest-news-card-1
Human Drugs

Pfizers Besponsa Expanded Use in Pediatric Leukemia

FDA approves Pfizers Besponsa (inotuzumab ozogamicin) for an expanded indication treating pediatric patients with relapsed or refractory CD22-positiv...